An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
Active, not recruiting · Phase 2 · NCT06254482
Conditions: Huntington Disease
At a glance
- Research payments reported, 2025
- $8,850
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 144
About the trial
- Sponsor
- Novartis Pharmaceuticals
- Tested
- Votoplam (drug)
- Dates
- Started 2023-08-25; completion 2029-07-16
- Results posted
- Not yet
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
From ClinicalTrials.gov, last updated 2025-11-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ptc Therapeutics, Inc. reported $8,850 in research payments for this study in 2025 (6 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $8,850
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.